Update to TMPPM Outpatient Drug Services Handbook
Date: February 7, 2025
Attention: All Providers
Effective date: January 1, 2025
Call to action: The purpose of this communication is to inform providers that on January 1, 2025, Texas Medicaid & Healthcare Partnership (TMHP) updated the Texas Medicaid Provider Procedures Manual (TMPPM), Outpatient Drug Services Handbook, section 6.104, “Ravulizumab-cwvz (Ultomiris)” and section 6.14, “Azacitidine (Vidaza).”
The following updates were made:
- Diagnosis code G360 will be added as a payable diagnosis for ravulizumab-cwvz (Ultomiris) (procedure code J1303).
- Diagnosis code C9200 will be added as a payable diagnosis for azacitidine (Vidaza) (procedure code J9025).
Next steps: Providers should share this communication with their staff.
If you have any questions, please email Provider Relations at: providerrelations@texaschildrens.org.
For access to all provider alerts,log into:
www.texaschildrenshealthplan.org/provideralerts.